Consolidated Statements of Cash Flows (USD $)	12 Months Ended		131 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities
Net loss	$ (16,656,325)	$ (8,930,833)	$ (126,267,945)
Adjustments to reconcile net loss to net cash used in operating activities
Stock payable for acquired research and development			112,440
Stock issued for acquired research and development			26,286,589
Stock issued for services	69,899		2,131,642
Stock issued for debt in excess of principal			109,070
Amortization of discount on notes payable due to warrants and beneficial conversion feature	1,613,354	104,032	8,470,084
Loss on extinguishment of debt	2,518,912		906,472
Depreciation	335,597	303,677	1,985,755
Amortization of debt financing costs	125,248	58,639	708,265
Option and warrant expense	1,129,640	690,726	17,395,573
(Gain) loss on derivative instruments		(552,978)	(1,941,826)
Loss on disposal of fixed assets	2,161	3,097	515,506
Changes in:
Other current assets	104,051	(611,607)	(1,049,002)
Accounts payable - third parties and related parties	147,923	(71,410)	(12,728)
Accrued expenses	928,549	83,018	1,533,787
Other assets	(177,667)		(177,667)
Deferred revenue	3,733,389		3,733,389
Net cash used in operating activities	(6,125,269)	(8,923,639)	(65,560,596)
Cash flows from investing activities
Purchase of property & equipment	(259,224)	(550,389)	(2,481,423)
Restricted cash	1,000,000	(1,000,000)
Net cash used in investing activities	740,776	(1,550,389)	(2,481,423)
Cash flows from financing activities
Common stock and warrants sold for cash, net of offering costs	28,484,878	381,309	77,938,675
Common stock repurchased and canceled			(325)
Proceeds from exercise of warrants and options			1,248,588
Deferred financing and offering costs	(147,847)	(509,492)	(657,339)
Repayments on notes payable	(450,000)		(761,222)
Net cash provided by financing activities	28,437,031	3,956,817	91,686,561
Net change in cash and cash equivalents	23,052,538	(6,517,211)	23,644,542
Cash and cash equivalents at beginning of period	592,004	7,109,215
Cash and cash equivalents at end of period	23,644,542	592,004	23,644,542
Cash paid for:
Income tax
Interest	19,648	1,946	174,757
NON-CASH TRANSACTIONS
Issuance of common stock to Sportan shareholders			147,733
Issuance of common stock for accrued interest	188,543	185,683	977,830
Issuance of warrants to placement agent			37,453
Conversion of notes payable to common stock	4,275,053		11,985,033
Conversion of accrued liabilities to common stock			197,176
Conversion of accounts payable to note payable			93,364
Discount on convertible notes relating to:
Warrants	195,969	2,314,635	6,170,341
Beneficial conversion feature	141,829	1,497,634	3,444,982
Stock attached to notes			1,287,440
Fair value of derivative instrument			4,680,220
Derivative reclassified to equity		1,761,657	2,349,266
Unpaid additions to property and equipment	108,516	7,812	108,516
Amortization of deferred offering costs to paid-in capital		47,339	47,339
Shares issued as deferred offering costs	1,234	149,131	150,365
Unpaid offering costs	136,776		136,776
Third Parties
Cash flows from financing activities
Proceeds from convertible debt	550,000	3,455,000	13,288,184
Related Parties
Cash flows from financing activities
Proceeds from convertible debt	100,000	630,000	730,000
Repayments on notes payable	$ (100,000)		$ (100,000)